Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FATE – Fate Therapeutics, Inc.

Fate Therapeutics, Inc.
FATE
$1.63
Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $186,278,624.00
EPSttm : -1.49
finviz dynamic chart for FATE
Fate Therapeutics, Inc.
$1.63
21.27%
$0.285

Float Short %

12.02

Margin Of Safety %

Put/Call OI Ratio

0.07

EPS Next Q Diff

EPS Last/This Y

0.38

EPS This/Next Y

0.15

Price

1.34

Target Price

5.44

Analyst Recom

2.36

Performance Q

28.85

Relative Volume

0.4

Beta

2.23

Ticker: FATE




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07FATE0.99980.2710.008393
2025-05-08FATE1.040.260.008392
2025-05-09FATE1.0350.260.008401
2025-05-12FATE1.060.260.008399
2025-05-13FATE10.260.008400
2025-05-14FATE0.96740.260.008394
2025-05-15FATE1.010.260.018396
2025-05-16FATE1.060.263.068418
2025-05-19FATE1.2150.080.004855
2025-05-20FATE1.260.080.005165
2025-05-21FATE1.160.080.005165
2025-05-22FATE1.190.080.005167
2025-05-23FATE1.170.080.005167
2025-05-27FATE1.220.080.005229
2025-05-28FATE1.2650.070.015305
2025-05-29FATE1.320.070.005448
2025-05-30FATE1.2150.070.015467
2025-06-02FATE1.290.070.005506
2025-06-03FATE1.360.070.005774
2025-06-04FATE1.4250.070.005787
2025-06-05FATE1.340.070.005876
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07FATE1.0019.3- -1.46
2025-05-08FATE1.0319.3- -1.46
2025-05-09FATE1.0419.3- -1.46
2025-05-12FATE1.0719.3- -1.46
2025-05-13FATE1.0019.3- -1.46
2025-05-14FATE0.9619.3- -1.46
2025-05-15FATE1.0119.3- -1.46
2025-05-16FATE1.0719.3- -1.46
2025-05-19FATE1.22-3.3- -1.25
2025-05-20FATE1.25-3.3- -1.25
2025-05-21FATE1.16-3.3- -1.25
2025-05-22FATE1.19-3.3- -1.25
2025-05-23FATE1.17-3.3- -1.25
2025-05-27FATE1.22-3.2- -1.26
2025-05-28FATE1.26-3.2- -1.26
2025-05-29FATE1.32-3.2- -1.26
2025-05-30FATE1.21-3.2- -1.26
2025-06-02FATE1.29-3.2- -1.26
2025-06-03FATE1.36-3.2- -1.26
2025-06-04FATE1.43-3.2- -1.26
2025-06-05FATE1.34-3.2- -1.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07FATE0.32-14.2015.06
2025-05-08FATE0.32-14.2015.06
2025-05-09FATE0.32-14.2015.06
2025-05-12FATE0.32-13.0012.89
2025-05-13FATE0.32-13.0012.89
2025-05-14FATE0.32-13.0012.89
2025-05-15FATE0.32-13.0012.89
2025-05-16FATE0.32-13.0012.89
2025-05-19FATE0.32-10.9112.46
2025-05-20FATE0.48-10.9112.46
2025-05-21FATE0.48-10.9112.46
2025-05-22FATE0.48-10.9112.46
2025-05-23FATE0.48-10.9112.46
2025-05-27FATE0.48-7.7612.46
2025-05-28FATE0.48-7.7612.02
2025-05-29FATE0.48-7.7612.02
2025-05-30FATE0.48-7.7612.02
2025-06-02FATE0.48-6.1612.02
2025-06-03FATE0.48-6.1612.02
2025-06-04FATE0.48-6.1612.02
2025-06-05FATE0.48-6.1612.02
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.32

Avg. EPS Est. Current Quarter

-0.34

Avg. EPS Est. Next Quarter

-0.32

Insider Transactions

0.48

Institutional Transactions

-6.16

Beta

2.23

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

16

Growth Score

34

Sentiment Score

43

Actual DrawDown %

98.9

Max Drawdown 5-Year %

-99.4

Target Price

5.44

P/E

Forward P/E

PEG

P/S

11.51

P/B

0.53

P/Free Cash Flow

EPS

-1.49

Average EPS Est. Cur. Y​

-1.26

EPS Next Y. (Est.)

-1.12

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1318.93

Relative Volume

0.4

Return on Equity vs Sector %

-85

Return on Equity vs Industry %

-67.2

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.2

EBIT Estimation

Fate Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading